2026 Nobel Prize in Physiology or Medicine awarded for optogenetics discovery

The Nobel Assembly at Karolinska Institutet announced that the 2026 Nobel Prize in Physiology or Medicine will be shared equally among Karl Deisseroth, MD, PhD, of the Howard Hughes Medical Institute and Stanford University; Peter Hegemann, PhD, of Humboldt University of Berlin; and Georg Nagel, PhD, of the University of Würzburg, “for their discoveries concerning light-gated ion channels and optogenetics.”¹ The prize carries 12 million Swedish kronor—approximately US $1.2 million at current exchange rates—to be split equally among the three laureates.¹

What the Nobel committee recognized

The discovery traces back to a basic question about pond algae: How does the single-celled organism Chlamydomonas sense light well enough to swim toward it? Hegemann and Nagel found the answer in the early 2000s in channelrhodopsin, a light-responsive protein they identified on the alga’s cell surface.¹ Expose the protein to blue light and it forms a pore that admits charged ions, producing an electrical current—and critically, the effect was not specific to algae. Any cell engineered to carry the protein gained the same light sensitivity.¹

Deisseroth saw the neuroscience application. He spliced the channelrhodopsin gene into neurons taken from rats and, in a 2005 paper, showed that a brief pulse of blue light was enough to fire them on command. Two years later he moved the technique into living animals, triggering neurons inside the brains of intact mice.¹

That light-activated switch is what the field now calls optogenetics, and it has since become a standard tool for isolating which specific neural circuits drive a given memory, emotion, or behavior, with implications for neurological and psychiatric disease.¹ Per Svenningsson, chair of the Nobel Committee for Physiology or Medicine, credited the method with “provid[ing] opportunities for mapping the brain in a way that we could once only dream of.”¹

Why ophthalmology is watching

Vision restoration is one of the clinical uses the Nobel Assembly itself highlighted. Its press release states that “researchers are using the method in attempts to restore sight in people with visual impairment.”¹ That strand of work has its own recent recognition in ophthalmology: Botond Roska and José-Alain Sahel won the 2026 António Champalimaud Vision Award, worth €1 million and billed by its organizers as the largest prize in the world for vision science, for more than two decades of research aimed at coaxing retinal cells that outlast disease-destroyed photoreceptors into sensing light on their own.²

That work produced a notable result in 2021, when the pair and their collaborators published findings in Nature Medicine showing that an optogenetic approach had partially restored visual function in a patient who had been blind from retinitis pigmentosa.²

A field with Nobel history

Vision research has been recognized by the Physiology or Medicine prize before. In 1967, Ragnar Granit, MD, shared the award with Haldan Keffer Hartline, MD, and George Wald, PhD, “for their discoveries concerning the primary physiological and chemical visual processes in the eye.” This year’s prize went to a method with applications that extend beyond vision, from mapping memory circuits to treating neurological and psychiatric disease, with sight restoration as one strand among several.¹

References

1. The 2026 Nobel Prize in Physiology or Medicine. Press release. The Nobel Assembly at Karolinska Institutet; October 5, 2026. Accessed October 5, 2026. https://www.nobelprize.org/prizes/medicine/2026/press-release/

2. Drs. Sahel and Roska share €1 million vision prize. Retinal Physician. September 16, 2026. Accessed October 5, 2026. https://www.retinalphysician.com/news/2026/sahel-and-roska-share-1-million-vision-prize/